Suppr超能文献

抗甲状腺药物治疗后格雷夫斯病患者发生自发性甲状腺功能减退的机制。

The mechanism of spontaneous hypothyroidism in patients with Graves' disease after antithyroid drug treatment.

作者信息

Tamai H, Hirota Y, Kasagi K, Matsubayashi S, Kuma K, Iida Y, Konishi J, Okimura M C, Walter R M, Kumagai L F

出版信息

J Clin Endocrinol Metab. 1987 Apr;64(4):718-22. doi: 10.1210/jcem-64-4-718.

Abstract

The natural course of Graves' disease results in hypothyroidism in up to 20% of patients previously treated with antithyroid drugs. The precise mechanisms are not known, although autoimmune destruction of thyroid tissue has been proposed. We studied sequentially obtained serum samples from three patients with hyperthyroid Graves' disease previously treated with an antithyroid drug who became hypothyroid to determine possible causes of their hypothyroidism. Antithyroglobulin and antithyroid microsomal autoantibodies, TSH binding inhibitory immunoglobulin (TBII), thyroid-stimulating antibody (TSAb), and thyroid stimulation-blocking activity were measured. Autoantibodies were markedly elevated throughout the clinical course in all three patients. Patient 1 had no TBII and blocking activity and extremely high TSAb when she was euthyroid as well as hypothyroid. Hypothyroidism was probably the result of autoimmune thyroid destruction. In patient 2, TSAb disappeared, and TBII and blocking activity increased markedly when she developed hypothyroidism, which thus appeared to result from blocking antibodies. Patient 3 had intermittent periods of hyper- and hypothyroidism before becoming and remaining euthyroid. While initially hypothyroid, TBII was weakly positive, and TSAb was strongly positive; subsequently, when hyperthyroidism recurred, TBII and TSAb were strongly positive. Hypothyroidism appeared to result from focal autoimmune thyroiditis. Patients with hyperthyroid Graves' disease may develop hypothyroidism later by different means. Autoimmune thyroiditis, diffuse or focal, with thyroid destruction is one mechanism. The appearance of antibodies that block TSH stimulation may be another.

摘要

格雷夫斯病的自然病程会导致高达20%曾接受抗甲状腺药物治疗的患者出现甲状腺功能减退。尽管有人提出甲状腺组织的自身免疫性破坏是其原因,但确切机制尚不清楚。我们对3例曾接受抗甲状腺药物治疗的甲状腺功能亢进的格雷夫斯病患者进行了研究,这些患者后来出现了甲状腺功能减退,我们对其序贯采集的血清样本进行检测,以确定其甲状腺功能减退的可能原因。检测了抗甲状腺球蛋白和抗甲状腺微粒体自身抗体、促甲状腺激素结合抑制性免疫球蛋白(TBII)、甲状腺刺激抗体(TSAb)以及甲状腺刺激阻断活性。在所有3例患者的整个临床病程中,自身抗体均显著升高。患者1在甲状腺功能正常以及甲状腺功能减退时均无TBII和阻断活性,而TSAb极高。甲状腺功能减退可能是自身免疫性甲状腺破坏的结果。患者2在出现甲状腺功能减退时,TSAb消失,而TBII和阻断活性显著增加,因此甲状腺功能减退似乎是由阻断抗体导致的。患者3在甲状腺功能正常之前有甲状腺功能亢进和减退的间歇期。最初甲状腺功能减退时,TBII弱阳性,TSAb强阳性;随后,当甲状腺功能亢进复发时,TBII和TSAb均强阳性。甲状腺功能减退似乎是由局灶性自身免疫性甲状腺炎导致的。甲状腺功能亢进的格雷夫斯病患者后期可能通过不同方式出现甲状腺功能减退。弥漫性或局灶性自身免疫性甲状腺炎伴甲状腺破坏是一种机制。阻断促甲状腺激素刺激的抗体的出现可能是另一种机制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验